JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer

Key Takeaways J&J won EU approval to expand Akeega use to BRCA1/2-mutated metastatic hormone-sensitive prostate cancer.JNJ's phase III AMPLITUDE study showed the combo nearly halved the risk of disease progression or death.Akeega was approved in the EU in 2023 for BRCA-mutated metastatic castration-resistant prostate cancer.J&J (JNJ) announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. T ...